Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
Crossref DOI link: https://doi.org/10.1186/s12913-017-1995-8
Published Online: 2017-01-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lanitis, Tereza
Leipold, Robert
Hamilton, Melissa
Rublee, Dale
Quon, Peter
Browne, Chantelle
Cohen, Alexander T.
Funding for this research was provided by:
Bristol-Myers Squibb
Pfizer